Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Side-effects news

Show

From To
Is Gilead’s Entire HIV Enterprise Built on a False Promise?

A new analysis finds that Gilead Sciences’ updated version of its key antiretroviral tenofovir may not actually offer any safety benefits.

Published
10 May 2018
From
Poz
Meta-analysis of dolutegravir in naive, experienced and switch studies

A meta-analysis of 7340 participants in 13 randomised trials found efficacy and safety benefits for starting dolutegravir compared with other antiretrovirals in both naive and experienced participants. In the four switch studies in participants with undetectable viral load on their current ART, however, changing to dolutegravir was associated with more adverse events and discontinuations.

Published
30 April 2018
From
HIV i-Base
TAF only superior to TDF when used with a boosting agent

The benefits of tenofovir alafenamide (TAF) over tenofovir disoproxil fumarate (TDF) may have been overstated, according to the results of a meta-analysis published in the

Published
10 April 2018
By
Michael Carter
More evidence shows Sustiva increases risk for suicidal behavior

Patients with HIV on a Sustiva-containing ART regimen had a threefold increased risk for suicidal behavior compared with ART-naive patients, according to recent data published in Clinical Infectious Diseases.

Published
26 March 2018
From
Healio
Taking multiple Rx drugs raises risks for aging adults with and without HIV

Taking five or more prescription medications increases the risk of hospitalization and death in older adults infected with HIV and comparable adults without HIV. The findings of this Yale-led study highlight the potential risks of prescribing additional drugs to patients with multiple medical conditions.

Published
01 February 2018
From
Yale News
Viral suppression protects against long-term liver damage caused by older HIV drugs

A history of treatment with some older antiretroviral drugs can have a lasting negative impact on liver health, German researchers report in PLOS One. They

Published
29 January 2018
By
Michael Carter
AZT: The phoenix of HIV treatment

During the last 30 years, over 15 million people have received AZT: an antiretroviral used to prevent HIV/AIDS. While it has now been replaced with other drugs in high income countries, it is still used widely in low-to-middle-income countries; this poses issues due to difficulties in detecting resistance to the drug and the side effects it carries. In this blog, author of a paper published in Infectious Disease of Poverty, Eric J. Arts, discusses his career long connection to AZT and the issues with AZT-based treatments in sub-Saharan Africa.

Published
24 January 2018
From
BMC Blogs Network (blog)
Study Finds Sustiva Not Strongly Linked to Suicidal Thoughts

But that is not necessarily the case for those with preexisting mental health problems.

Published
31 December 2017
From
Poz
Marijuana Could Be Huge for Treating HIV

From inflammation to lowering levels of the virus itself, a current study hopes to demystify pot's benefits for those living with HIV.

Published
17 November 2017
From
VICE
Gilead’s Updated Version of Tenofovir Performs Well Among Blacks With HIV

Compared with the older tenofovir, called TDF, the new one, TAF, suppressed the virus as well and offered bone, kidney and lipid benefits.

Published
18 October 2017
From
Poz
← First12345...78Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.